Viron Therapeutics Inc. Reports Positive Proof of Concept Results in Arthritis for its VT-346 Anti-TNF Therapeutic
3/16/2010 8:44:55 AM
More...
|
Viron Therapeutics Inc. Granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
12/22/2009 9:02:49 AM
More...
|
Viron Therapeutics Inc. to Present Data from Phase II Trial at American Heart Association Conference
11/12/2009 8:21:06 AM
More...
|
Viron Therapeutics Inc. Appoints Claude Benedict, M.D. as New Senior Vice President, Clinical Development and Regulatory Affairs
5/1/2007 1:14:26 PM
More...
|
Viron Therapeutics Inc. Signs Agreement With Diosynth Biotechnology For Clinical Manufacturing Of VT-111
10/25/2006 10:34:38 AM
More...
|
Viron Therapeutics Inc. Signs Agreement With Diosynth Biotechnology For Clinical Manufacturing Of VT-111
10/24/2006 11:18:04 AM
More...
|
Viron Therapeutics Inc.'s VT-111 Among Top 10 Most Promising Drugs
10/4/2006 2:16:20 PM
More...
|
Viron Therapeutics Raises US $20 Million Series A Financing; Positions Viron To Complete Phase II Trial And Advance Additional Compounds Into Clinical Development
5/16/2006 10:32:43 AM
More...
|
Viron Therapeutics Wins Prestigious 2005 Prix Galien Award
11/14/2005 11:27:55 AM
More...
|
Viron Therapeutics Initiates Phase 2 Clinical Trial Of Novel Anti-Inflammatory For Acute Coronary Syndromes
10/19/2005 5:12:47 PM
More...
|
|